Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 10Withdrawn 3Unknown 3Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1

Interventions

pembrolizumab 70Nivolumab 36Cyclophosphamide 34Carboplatin 28Dexamethasone 23Specimen Handling 22Paclitaxel 22Lenalidomide 22durvalumab 19Radiotherapy 19Gemcitabine 19venetoclax 18Magnetic Resonance Spectroscopy 18Doxorubicin 17Rituximab 16fludarabine 15Ipilimumab 15Bevacizumab 15Cisplatin 14Biopsy 14atezolizumab 13Etoposide 13Vincristine 12Pemetrexed 12belantamab mafodotin 11Docetaxel 11Calcium Dobesilate 11Azacitidine 11olaparib 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Active not recruiting × Ascorbic Acid × Clear all
NCT04046094 2025-03-25

Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients

University of Kansas Medical Center

Phase 1/2 Active not recruiting
12 enrolled 9 charts
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡